Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus.

Jasenosky LD, Cadena C, Mire CE, Borisevich V, Haridas V, Ranjbar S, Nambu A, Bavari S, Soloveva V, Sadukhan S, Cassell GH, Geisbert TW, Hur S, Goldfeld AE.

iScience. 2019 Sep 27;19:1279-1290. doi: 10.1016/j.isci.2019.07.003. Epub 2019 Aug 8.

2.

Treatment of drug-resistant tuberculosis among people living with HIV.

Hurtado RM, Meressa D, Goldfeld AE.

Curr Opin HIV AIDS. 2018 Nov;13(6):478-485. doi: 10.1097/COH.0000000000000503. Review.

PMID:
30286039
3.

Initiation, scale-up and outcomes of the Cambodian National MDR-TB programme 2006-2016: hospital and community-based treatment through an NGO-NTP partnership.

Sam S, Shapiro AE, Sok T, Khann S, So R, Khem S, Chhun S, Noun S, Koy B, Sayouen PC, Im Sin C, Bunsieth H, Mao TE, Goldfeld AE.

BMJ Open Respir Res. 2018 Jun 4;5(1):e000256. doi: 10.1136/bmjresp-2017-000256. eCollection 2018.

4.

Diagnostic Potential of Imaging Flow Cytometry.

Doan M, Vorobjev I, Rees P, Filby A, Wolkenhauer O, Goldfeld AE, Lieberman J, Barteneva N, Carpenter AE, Hennig H.

Trends Biotechnol. 2018 Jul;36(7):649-652. doi: 10.1016/j.tibtech.2017.12.008. Epub 2018 Jan 31.

5.

Imaging flow cytometry analysis of intracellular pathogens.

Haridas V, Ranjbar S, Vorobjev IA, Goldfeld AE, Barteneva NS.

Methods. 2017 Jan 1;112:91-104. doi: 10.1016/j.ymeth.2016.09.007. Epub 2016 Sep 15. Review.

6.

A Role for IFITM Proteins in Restriction of Mycobacterium tuberculosis Infection.

Ranjbar S, Haridas V, Jasenosky LD, Falvo JV, Goldfeld AE.

Cell Rep. 2015 Nov 3;13(5):874-83. doi: 10.1016/j.celrep.2015.09.048. Epub 2015 Oct 22.

7.

Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia--an observational cohort study.

Meressa D, Hurtado RM, Andrews JR, Diro E, Abato K, Daniel T, Prasad P, Prasad R, Fekade B, Tedla Y, Yusuf H, Tadesse M, Tefera D, Ashenafi A, Desta G, Aderaye G, Olson K, Thim S, Goldfeld AE.

Thorax. 2015 Dec;70(12):1181-8. doi: 10.1136/thoraxjnl-2015-207374. Epub 2015 Oct 27.

8.

T cells and adaptive immunity to Mycobacterium tuberculosis in humans.

Jasenosky LD, Scriba TJ, Hanekom WA, Goldfeld AE.

Immunol Rev. 2015 Mar;264(1):74-87. doi: 10.1111/imr.12274. Review.

PMID:
25703553
9.

TB-IRIS, T-cell activation, and remodeling of the T-cell compartment in highly immunosuppressed HIV-infected patients with TB.

Haridas V, Pean P, Jasenosky LD, Madec Y, Laureillard D, Sok T, Sath S, Borand L, Marcy O, Chan S, Tsitsikov E, Delfraissy JF, Blanc FX, Goldfeld AE; CAPRI-T (ANRS 12164) Study Team.

AIDS. 2015 Jan 28;29(3):263-73. doi: 10.1097/QAD.0000000000000546.

10.

A distal locus element mediates IFN-γ priming of lipopolysaccharide-stimulated TNF gene expression.

Chow NA, Jasenosky LD, Goldfeld AE.

Cell Rep. 2014 Dec 11;9(5):1718-1728. doi: 10.1016/j.celrep.2014.11.011. Epub 2014 Dec 4.

11.

Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial.

Marcy O, Laureillard D, Madec Y, Chan S, Mayaud C, Borand L, Prak N, Kim C, Lak KK, Hak C, Dim B, Sok T, Delfraissy JF, Goldfeld AE, Blanc FX; CAMELIA (ANRS 1295-CIPRA KH001) Study Team.

Clin Infect Dis. 2014 Aug 1;59(3):435-45. doi: 10.1093/cid/ciu283. Epub 2014 Apr 23.

12.

Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial).

Borand L, Madec Y, Laureillard D, Chou M, Marcy O, Pheng P, Prak N, Kim C, Lak KK, Hak C, Dim B, Nerrienet E, Fontanet A, Sok T, Goldfeld AE, Blanc FX, Taburet AM.

PLoS One. 2014 Mar 7;9(3):e90350. doi: 10.1371/journal.pone.0090350. eCollection 2014.

13.

Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial.

Laureillard D, Marcy O, Madec Y, Chea S, Chan S, Borand L, Fernandez M, Prak N, Kim C, Dim B, Nerrienet E, Sok T, Delfraissy JF, Goldfeld AE, Blanc FX; CAMELIA (ANRS 1295 – CIPRA KH001) Study Team.

AIDS. 2013 Oct 23;27(16):2577-86. doi: 10.1097/01.aids.0000432456.14099.c7.

PMID:
24096631
14.

Epigenetic control of cytokine gene expression: regulation of the TNF/LT locus and T helper cell differentiation.

Falvo JV, Jasenosky LD, Kruidenier L, Goldfeld AE.

Adv Immunol. 2013;118:37-128. doi: 10.1016/B978-0-12-407708-9.00002-9. Review.

15.

Plasma concentrations of efavirenz with a 600 mg standard dose in Cambodian HIV-infected adults treated for tuberculosis with a body weight above 50 kg.

Borand L, Laureillard D, Madec Y, Chou M, Pheng P, Marcy O, Sok T, Goldfeld AE, Taburet AM, Blanc FX; CAMELIA ANRS 1295-CIPRA KH001 Study Team.

Antivir Ther. 2013;18(3):419-23. doi: 10.3851/IMP2483. Epub 2012 Dec 12.

PMID:
23237982
16.

The transcription factor NFATp plays a key role in susceptibility to TB in mice.

Via LE, Tsytsykova AV, Rajsbaum R, Falvo JV, Goldfeld AE.

PLoS One. 2012;7(7):e41427. doi: 10.1371/journal.pone.0041427. Epub 2012 Jul 23.

17.

Regulation of Mycobacterium tuberculosis-dependent HIV-1 transcription reveals a new role for NFAT5 in the toll-like receptor pathway.

Ranjbar S, Jasenosky LD, Chow N, Goldfeld AE.

PLoS Pathog. 2012;8(4):e1002620. doi: 10.1371/journal.ppat.1002620. Epub 2012 Apr 5.

18.

Monocyte-specific accessibility of a matrix attachment region in the tumor necrosis factor locus.

Biglione S, Tsytsykova AV, Goldfeld AE.

J Biol Chem. 2011 Dec 23;286(51):44126-33. doi: 10.1074/jbc.M111.272476. Epub 2011 Oct 25.

19.

Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.

Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y, Marcy O, Chan S, Prak N, Kim C, Lak KK, Hak C, Dim B, Sin CI, Sun S, Guillard B, Sar B, Vong S, Fernandez M, Fox L, Delfraissy JF, Goldfeld AE; CAMELIA (ANRS 1295–CIPRA KH001) Study Team.

N Engl J Med. 2011 Oct 20;365(16):1471-81. doi: 10.1056/NEJMoa1013911.

20.

The use of HaloTag-based technology in flow and laser scanning cytometry analysis of live and fixed cells.

Kovalenko EI, Ranjbar S, Jasenosky LD, Goldfeld AE, Vorobjev IA, Barteneva NS.

BMC Res Notes. 2011 Sep 9;4:340. doi: 10.1186/1756-0500-4-340.

21.

Arc of a vicious circle: pathways activated by Mycobacterium tuberculosis that target the HIV-1 long terminal repeat.

Falvo JV, Ranjbar S, Jasenosky LD, Goldfeld AE.

Am J Respir Cell Mol Biol. 2011 Dec;45(6):1116-24. doi: 10.1165/rcmb.2011-0186TR. Epub 2011 Aug 18. Review.

22.

Transcriptional control of the TNF gene.

Falvo JV, Tsytsykova AV, Goldfeld AE.

Curr Dir Autoimmun. 2010;11:27-60. doi: 10.1159/000289196. Epub 2010 Feb 18. Review.

23.

HIV-1 replication is differentially regulated by distinct clinical strains of Mycobacterium tuberculosis.

Ranjbar S, Boshoff HI, Mulder A, Siddiqi N, Rubin EJ, Goldfeld AE.

PLoS One. 2009 Jul 1;4(7):e6116. doi: 10.1371/journal.pone.0006116.

24.

A dimer-specific function of the transcription factor NFATp.

Falvo JV, Lin CH, Tsytsykova AV, Hwang PK, Thanos D, Goldfeld AE, Maniatis T.

Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19637-42. doi: 10.1073/pnas.0810648105. Epub 2008 Dec 5.

25.

Activation-dependent intrachromosomal interactions formed by the TNF gene promoter and two distal enhancers.

Tsytsykova AV, Rajsbaum R, Falvo JV, Ligeiro F, Neely SR, Goldfeld AE.

Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):16850-5. Epub 2007 Oct 16.

26.

Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials.

Blanc FX, Havlir DV, Onyebujoh PC, Thim S, Goldfeld AE, Delfraissy JF.

J Infect Dis. 2007 Aug 15;196 Suppl 1:S46-51. Review.

PMID:
17624825
27.

Primate TNF promoters reveal markers of phylogeny and evolution of innate immunity.

Baena A, Mootnick AR, Falvo JV, Tsytskova AV, Ligeiro F, Diop OM, Brieva C, Gagneux P, O'Brien SJ, Ryder OA, Goldfeld AE.

PLoS One. 2007 Jul 18;2(7):e621.

28.

Post-induction, stimulus-specific regulation of tumor necrosis factor mRNA expression.

Tsytsykova AV, Falvo JV, Schmidt-Supprian M, Courtois G, Thanos D, Goldfeld AE.

J Biol Chem. 2007 Apr 20;282(16):11629-38. Epub 2007 Feb 15.

29.

NFAT5 regulates HIV-1 in primary monocytes via a highly conserved long terminal repeat site.

Ranjbar S, Tsytsykova AV, Lee SK, Rajsbaum R, Falvo JV, Lieberman J, Shankar P, Goldfeld AE.

PLoS Pathog. 2006 Dec;2(12):e130.

31.

Geographical distribution and disease associations of the CD45 exon 6 138G variant.

Ward V, Hennig BJ, Hirai K, Tahara H, Tamori A, Dawes R, Saito M, Bangham C, Stephens H, Goldfeld AE, Kunachiwa W, Leetrakool N, Hopkin J, Dunstan S, Hill A, Bodmer W, Beverley PC, Tchilian EZ.

Immunogenetics. 2006 Apr;58(2-3):235-9. Epub 2006 Mar 15.

PMID:
16538473
32.
33.

NFAT5 binds to the TNF promoter distinctly from NFATp, c, 3 and 4, and activates TNF transcription during hypertonic stress alone.

Esensten JH, Tsytsykova AV, Lopez-Rodriguez C, Ligeiro FA, Rao A, Goldfeld AE.

Nucleic Acids Res. 2005 Jul 12;33(12):3845-54. Print 2005.

34.

Identification of a macrophage-specific chromatin signature in the IL-10 locus.

Saraiva M, Christensen JR, Tsytsykova AV, Goldfeld AE, Ley SC, Kioussis D, O'Garra A.

J Immunol. 2005 Jul 15;175(2):1041-6.

35.

IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage.

O'Garra A, Vieira PL, Vieira P, Goldfeld AE.

J Clin Invest. 2004 Nov;114(10):1372-8. Review.

36.

Diagnostic and clinical implications of response to tuberculin in two ethnically distinct populations from Peru and Cambodia.

Delgado JC, Quiñones-Berrocal J, Thim S, Miranda LF, Goldfeld AE.

Int J Tuberc Lung Dis. 2004 Aug;8(8):982-7.

PMID:
15305481
37.

A community-based tuberculosis program in Cambodia.

Thim S, Sath S, Sina M, Tsai EY, Delgado JC, Shapiro AE, Barry CE 3rd, Glaziou P, Goldfeld AE.

JAMA. 2004 Aug 4;292(5):566-8. No abstract available.

PMID:
15292081
38.
39.

Genetic susceptibility to pulmonary tuberculosis in Cambodia.

Goldfeld AE.

Tuberculosis (Edinb). 2004;84(1-2):76-81. Review.

PMID:
14670348
40.

The -1030/-862-linked TNF promoter single-nucleotide polymorphisms are associated with the inability to control HIV-1 viremia.

Delgado JC, Leung JY, Baena A, Clavijo OP, Vittinghoff E, Buchbinder S, Wolinsky S, Addo M, Walker BD, Yunis EJ, Goldfeld AE.

Immunogenetics. 2003 Oct;55(7):497-501. Epub 2003 Sep 27.

PMID:
14517700
42.

Regulation of tumor necrosis factor alpha gene expression by mycobacteria involves the assembly of a unique enhanceosome dependent on the coactivator proteins CBP/p300.

Barthel R, Tsytsykova AV, Barczak AK, Tsai EY, Dascher CC, Brenner MB, Goldfeld AE.

Mol Cell Biol. 2003 Jan;23(2):526-33.

43.

TNF-alpha promoter single nucleotide polymorphisms are markers of human ancestry.

Baena A, Leung JY, Sullivan AD, Landires I, Vasquez-Luna N, Quiñones-Berrocal J, Fraser PA, Uko GP, Delgado JC, Clavijo OP, Thim S, Meshnick SR, Nyirenda T, Yunis EJ, Goldfeld AE.

Genes Immun. 2002 Dec;3(8):482-7.

44.

Ethnic-specific genetic associations with pulmonary tuberculosis.

Delgado JC, Baena A, Thim S, Goldfeld AE.

J Infect Dis. 2002 Nov 15;186(10):1463-8. Epub 2002 Oct 16.

PMID:
12404162
45.

Antigen-specific and persistent tuberculin anergy in a cohort of pulmonary tuberculosis patients from rural Cambodia.

Delgado JC, Tsai EY, Thim S, Baena A, Boussiotis VA, Reynes JM, Sath S, Grosjean P, Yunis EJ, Goldfeld AE.

Proc Natl Acad Sci U S A. 2002 May 28;99(11):7576-81.

46.
47.

Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity.

Flores-Villanueva PO, Yunis EJ, Delgado JC, Vittinghoff E, Buchbinder S, Leung JY, Uglialoro AM, Clavijo OP, Rosenberg ES, Kalams SA, Braun JD, Boswell SL, Walker BD, Goldfeld AE.

Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5140-5. Epub 2001 Apr 17.

48.

Post-genomics and the neutral theory: variation and conservation in the tumor necrosis factor-alpha promoter.

Goldfeld AE, Leung JY, Sawyer SA, Hartl DL.

Gene. 2000 Dec 30;261(1):19-25.

PMID:
11164033
49.
50.

A lipopolysaccharide-specific enhancer complex involving Ets, Elk-1, Sp1, and CREB binding protein and p300 is recruited to the tumor necrosis factor alpha promoter in vivo.

Tsai EY, Falvo JV, Tsytsykova AV, Barczak AK, Reimold AM, Glimcher LH, Fenton MJ, Gordon DC, Dunn IF, Goldfeld AE.

Mol Cell Biol. 2000 Aug;20(16):6084-94.

Supplemental Content

Loading ...
Support Center